First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in Newly-diagnosed Glioblastoma Multiforme in Taiwan First CANbridge Clinical Trial
Sep 26, 2016
CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody,CAN-017,for Esophageal Squamous Cell Cancer
Aug 11, 2016
CANbridge’s CAN-008 Approved for Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan
Jul 26, 2016
CANbridge Appoints Dr. Huai Zhong Hu as Vice President of Preclinical Development
Jul 05, 2016
CANbridge Life Sciences ltd. Elected to be a Member of Phirda
Jun 03, 2016
James Xue, Founder and CEO of CANbridge, Present at 2016 Boston CEO Conference
May 29, 2016
CANbridge Submits Investigational New Drug Application to Taiwan Food and Drug Administration for CAN-008 Phase I/II Trial in Glioblastoma Selects WuXi Biologics to Manufacture CAN-008 for the China Market
Apr 07, 2016
AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North America
Mar 22, 2016
CANbridge Completes Chinese Glioblastoma Biomarker Study for Lead Candidate, CAN008 Plans to Initiate Phase I/II Trial in Taiwan in 2016
Jan 11, 2016